📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Targeting the ATR-CHK1 Axis in Cancer Therapy. (2017)

First Author: Rundle S

Attributed to: Understanding synthetic lethality of ATR inhibitors with DDR dysregulation common in ovarian cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3390/cancers9050041

PubMed Identifier: 28448462

Publication URI: http://europepmc.org/abstract/MED/28448462

Type: Journal Article/Review

Volume: 9

Parent Publication: Cancers

Issue: 5

ISSN: 2072-6694